Celsion Corporation Prices $4.8 Million Registered Direct Offering LAWRENCEVILLE, NJ, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into securities purchase agreements with...

Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range...

Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today...